首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents
【24h】

Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents

机译:基于哌嗪的趋化因子受体CCR5拮抗剂作为抗前列腺癌药物的设计,合成和表征

获取原文
获取原文并翻译 | 示例
           

摘要

Chemokine receptor CCR5 plays an important role in the pro-inflammatory environment that aids in the proliferation of prostate cancer cells. Previously, a series of CCR5 antagonists containing a piperidine ring core skeleton were designed based upon the proposed CCR5 antagonist pharmacophore from molecular modeling studies. The developed CCR5 antagonists were able to antagonize CCR5 at a micromolar level and inhibit the proliferation of metastatic prostate cancer cell lines. In order to further explore the structure-activity-relationship of the pharmacophore identified, the molecular scaffold was expanded to contain a piperazine ring as the core. A number of compounds that were synthesized showed promising anti prostate cancer activity and reasonable cytotoxicity profiles based on the biological characterization.
机译:趋化因子受体CCR5在有助于前列腺癌细胞增殖的促炎环境中起重要作用。以前,基于分子模型研究提出的CCR5拮抗剂药效基团,设计了一系列含有哌啶环核心骨架的CCR5拮抗剂。开发的CCR5拮抗剂能够以微摩尔水平拮抗CCR5,并抑制转移性前列腺癌细胞系的增殖。为了进一步探索已鉴定的药效基团的结构-活性-关系,将分子支架扩展至包含哌嗪环作为核心。基于生物学特征,合成的许多化合物显示出有希望的抗前列腺癌活性和合理的细胞毒性谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号